The US Centers for Medicare and Medicaid Services is taking at least one message away from the first round of patient feedback meetings it hosted as part of the Medicare drug price negotiation process: the format it used in 2023 did not work particularly well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?